FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 347:1566-1575 November 14, 2002 Number 20 Next

	Full Text PDF PDA Full Text PowerPoint Slide Set Perspective by Sutherland, R. L. Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article PubMed Citation

ABSTRACT

Background Cyclin E, a regulator of the cell cycle, affects the behavior of breast-cancer cells. We investigated whether levels of cyclin E in the tumor correlated with survival among patients with breast cancer.

Methods Tumor tissue from 395 patients with breast cancer was assayed for cyclin E, cyclin D1, cyclin D3, and the HER-2/neu oncogene with the use of Western blot analysis. Full-length, low-molecular-weight, and total cyclin E were measured. Immunohistochemical assessments of cyclin E were also made of 256 tumors. We sought correlations between levels of these molecular markers and disease-specific and overall survival.

Results The median follow-up was 6.4 years. A high level of the low-molecular-weight isoforms of cyclin E, as detected by Western blotting, correlated strongly with disease-specific survival whether axillary lymph nodes were negative or positive for metastases (P<0.001). Among 114 patients with stage I breast cancer, none of the 102 patients with low levels of cyclin E in the tumor had died of breast cancer by five years after diagnosis, whereas all 12 patients with a high level of low-molecular-weight cyclin E had died of breast cancer within that period. In multivariate analysis, a high total cyclin E level or high levels of the low-molecular-weight forms of cyclin E were significantly correlated with poor outcome. The hazard ratio for death from breast cancer for patients with high total cyclin E levels as compared with those with low total cyclin E levels was 13.3 — about eight times as high as the hazard ratios associated with other independent clinical and pathological risk factors.

Conclusions Levels of total cyclin E and low-molecular-weight cyclin E in tumor tissue, as measured by Western blot assay, correlate strongly with survival in patients with breast cancer.

Source Information

From the Department of Experimental Radiation Oncology (K.K.), the Breast Cancer Research Program (K.K., T.A.B., M.C., G.N.H.), the Department of Biomathematics (S.L.T.), the Division of Radiation Oncology (T.A.B., M.C.), the Department of Breast Medical Oncology (G.N.H.), and the Department of Surgical Oncology (I.B.), University of Texas M.D. Anderson Cancer Center, Houston; the Division of Molecular Medicine, Wadsworth Center, Albany, N.Y. (Y.D., C.K., W.T., M.L., T.W.H.); and Quantitative Diagnostic Laboratories, Elmhurst, Ill. (S.S.B.).

Address reprint requests to Dr. Keyomarsi at the Department of Experimental Radiation Oncology, University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Box 66, Houston, TX 77030-4095, or at kkeyomar{at}mdanderson.org.

Full Text of this Article

Related Letters:

Cyclin E in Breast Cancer
Kang Y., D'Hondt L., André M., Canon J.-L., Yee D., Rabinowitz I., Bedrosian I., Tucker S. L., Keyomarsi K.
Extract | Full Text | PDF  
N Engl J Med 2003; 348:1063-1064, Mar 13, 2003. Correspondence

This article has been cited by other articles:

• Xiang, B., Chatti, K., Qiu, H., Lakshmi, B., Krasnitz, A., Hicks, J., Yu, M., Miller, W. T., Muthuswamy, S. K. (2008). Brk is coamplified with ErbB2 to promote proliferation in breast cancer. Proc. Natl. Acad. Sci. USA 105: 12463-12468 [Abstract] [Full Text]  
• Jeruss, J. S., Mittendorf, E. A., Tucker, S. L., Gonzalez-Angulo, A. M., Buchholz, T. A., Sahin, A. A., Cormier, J. N., Buzdar, A. U., Hortobagyi, G. N., Hunt, K. K. (2008). Staging of Breast Cancer in the Neoadjuvant Setting. Cancer Res. 68: 6477-6481 [Abstract] [Full Text]  
• Zeng, L., Geng, Y., Tretiakova, M., Yu, X., Sicinski, P., Kroll, T. G. (2008). Peroxisome Proliferator-Activated Receptor-{delta} Induces Cell Proliferation by a Cyclin E1-Dependent Mechanism and Is Up-regulated in Thyroid Tumors. Cancer Res. 68: 6578-6586 [Abstract] [Full Text]  
• Goulet, B., Markovic, Y., Leduy, L., Nepveu, A. (2008). Proteolytic Processing of Cut Homeobox 1 by Neutrophil Elastase in the MV4;11 Myeloid Leukemia Cell Line. Mol Cancer Res 6: 644-653 [Abstract] [Full Text]  
• Schildkraut, J. M., Moorman, P. G., Bland, A. E., Halabi, S., Calingaert, B., Whitaker, R., Lee, P. S., Elkins-Williams, T., Bentley, R. C., Marks, J. R., Berchuck, A. (2008). Cyclin E Overexpression in Epithelial Ovarian Cancer Characterizes an Etiologic Subgroup. Cancer Epidemiol. Biomarkers Prev. 17: 585-593 [Abstract] [Full Text]  
• Milne, A N A, Carvalho, R, Jansen, M, Kranenbarg, E K, van de Velde, C J H, Morsink, F M, Musler, A R, Weterman, M A J, Offerhaus, G J A (2008). Cyclin E low molecular weight isoforms occur commonly in early-onset gastric cancer and independently predict survival. J. Clin. Pathol. 61: 311-316 [Abstract] [Full Text]  
• Yarosh, W., Barrientos, T., Esmailpour, T., Lin, L., Carpenter, P. M., Osann, K., Anton-Culver, H., Huang, T. (2008). TBX3 Is Overexpressed in Breast Cancer and Represses p14ARF by Interacting with Histone Deacetylases. Cancer Res. 68: 693-699 [Abstract] [Full Text]  
• Berglund, P, Stighall, M, Jirstrom, K, Ryden, L, Ferno, M, Nordenskjold, B, Landberg, G (2008). Cyclin E confers a prognostic value in premenopausal breast cancer patients with tumours exhibiting an infiltrative growth pattern. J. Clin. Pathol. 61: 184-191 [Abstract] [Full Text]  
• Kim, S. J., Nakayama, S., Miyoshi, Y., Taguchi, T., Tamaki, Y., Matsushima, T., Torikoshi, Y., Tanaka, S., Yoshida, T., Ishihara, H., Noguchi, S. (2008). Determination of the specific activity of CDK1 and CDK2 as a novel prognostic indicator for early breast cancer. Ann Oncol 19: 68-72 [Abstract] [Full Text]  
• Harris, L., Fritsche, H., Mennel, R., Norton, L., Ravdin, P., Taube, S., Somerfield, M. R., Hayes, D. F., Bast, R. C. Jr (2007). American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer. JCO 25: 5287-5312 [Abstract] [Full Text]  
• Bedrosian, I., Lee, C., Tucker, S. L., Palla, S. L., Lu, K., Keyomarsi, K. (2007). Cyclin E Associated Kinase Activity Predicts Response to Platinum-Based Chemotherapy. Clin. Cancer Res. 13: 4800-4806 [Abstract] [Full Text]  
• Akli, S., Van Pelt, C. S., Bui, T., Multani, A. S., Chang, S., Johnson, D., Tucker, S., Keyomarsi, K. (2007). Overexpression of the Low Molecular Weight Cyclin E in Transgenic Mice Induces Metastatic Mammary Carcinomas through the Disruption of the ARF-p53 Pathway. Cancer Res. 67: 7212-7222 [Abstract] [Full Text]  
• Keck, J. M., Summers, M. K., Tedesco, D., Ekholm-Reed, S., Chuang, L.-C., Jackson, P. K., Reed, S. I. (2007). Cyclin E overexpression impairs progression through mitosis by inhibiting APCCdh1. J. Cell Biol. 178: 371-385 [Abstract] [Full Text]  
• Span, P. N., de Mulder, P. H., Sweep, F. C. G. J. (2007). Re: p27Kip1 and Cyclin E Expression and Breast Cancer Survival After Treatment With Adjuvant Chemotherapy. JNCI J Natl Cancer Inst 99: 738-738 [Full Text]  
• Li, H., Yao, L., Ouyang, T., Li, J., Wang, T., Fan, Z., Fan, T., Dong, B., Lin, B., Li, J., Xie, Y. (2007). Association of p73 G4C14-to-A4T14 (GC/AT) polymorphism with breast cancer survival. Carcinogenesis 28: 372-377 [Abstract] [Full Text]  
• Porter, P. L., Barlow, W. E., Yeh, I-T., Lin, M. G., Yuan, X. P., Donato, E., Sledge, G. W., Shapiro, C. L., Ingle, J. N., Haskell, C. M., Albain, K. S., Roberts, J. M., Livingston, R. B., Hayes, D. F. (2006). p27Kip1 and Cyclin E Expression and Breast Cancer Survival After Treatment With Adjuvant Chemotherapy. JNCI J Natl Cancer Inst 98: 1723-1731 [Abstract] [Full Text]  
• Skalicky, D. A., Kench, J. G., Segara, D., Coleman, M. J., Sutherland, R. L., Henshall, S. M., Musgrove, E. A., Biankin, A. V. (2006). Cyclin e expression and outcome in pancreatic ductal adenocarcinoma.. Cancer Epidemiol. Biomarkers Prev. 15: 1941-1947 [Abstract] [Full Text]  
• Bay, B.-H., Jin, R., Huang, J., Tan, P.-H. (2006). Metallothionein as a prognostic biomarker in breast cancer.. Exp. Biol. Med. 231: 1516-1521 [Abstract] [Full Text]  
• Wang, L, Peng, L, Dong, B, Kong, L, Meng, L, Yan, L, Xie, Y, Shou, C (2006). Overexpression of phosphatase of regenerating liver-3 in breast cancer: association with a poor clinical outcome. Ann Oncol 17: 1517-1522 [Abstract] [Full Text]  
• Ishii, Y., Pirkmaier, A., Alvarez, J. V., Frank, D. A., Keselman, I., Logothetis, D., Mandeli, J., O'Connell, M. J., Waxman, S., Germain, D. (2006). Cyclin d1 overexpression and response to bortezomib treatment in a breast cancer model.. JNCI J Natl Cancer Inst 98: 1238-1247 [Abstract] [Full Text]  
• El Messaoudi, S., Fabbrizio, E., Rodriguez, C., Chuchana, P., Fauquier, L., Cheng, D., Theillet, C., Vandel, L., Bedford, M. T., Sardet, C. (2006). Coactivator-associated arginine methyltransferase 1 (CARM1) is a positive regulator of the Cyclin E1 gene. Proc. Natl. Acad. Sci. USA 103: 13351-13356 [Abstract] [Full Text]  
• Kim, S. S., Cao, L., Lim, S.-C., Li, C., Wang, R.-H., Xu, X., Bachelier, R., Deng, C.-X. (2006). Hyperplasia and Spontaneous Tumor Development in the Gynecologic System in Mice Lacking the BRCA1-{Delta}11 Isoform.. Mol. Cell. Biol. 26: 6983-6992 [Abstract] [Full Text]  
• Guo, X., Hartley, R. S. (2006). HuR Contributes to Cyclin E1 Deregulation in MCF-7 Breast Cancer Cells. Cancer Res. 66: 7948-7956 [Abstract] [Full Text]  
• Spruck, C., Sun, D., Fiegl, H., Marth, C., Mueller-Holzner, E., Goebel, G., Widschwendter, M., Reed, S. I. (2006). Detection of low molecular weight derivatives of cyclin e1 is a function of cyclin e1 protein levels in breast cancer.. Cancer Res. 66: 7355-7360 [Abstract] [Full Text]  
• Sieuwerts, A. M., Look, M. P., Meijer-van Gelder, M. E., Timmermans, M., Trapman, A. M.A.C., Garcia, R. R., Arnold, M., Goedheer, A. J.W., de Weerd, V., Portengen, H., Klijn, J. G.M., Foekens, J. A. (2006). Which cyclin e prevails as prognostic marker for breast cancer? Results from a retrospective study involving 635 lymph node-negative breast cancer patients.. Clin. Cancer Res. 12: 3319-3328 [Abstract] [Full Text]  
• Payton, M., Chung, G., Yakowec, P., Wong, A., Powers, D., Xiong, L., Zhang, N., Leal, J., Bush, T. L., Santora, V., Askew, B., Tasker, A., Radinsky, R., Kendall, R., Coats, S. (2006). Discovery and Evaluation of Dual CDK1 and CDK2 Inhibitors.. Cancer Res. 66: 4299-4308 [Abstract] [Full Text]  
• Callagy, G. M., Pharoah, P. D., Pinder, S. E., Hsu, F. D., Nielsen, T. O., Ragaz, J., Ellis, I. O., Huntsman, D., Caldas, C. (2006). Bcl-2 Is a Prognostic Marker in Breast Cancer Independently of the Nottingham Prognostic Index. Clin. Cancer Res. 12: 2468-2475 [Abstract] [Full Text]  
• Shapiro, G. I. (2006). Cyclin-Dependent Kinase Pathways As Targets for Cancer Treatment. JCO 24: 1770-1783 [Abstract] [Full Text]  
• Potemski, P., Pluciennik, E., Bednarek, A. K., Kusinska, R., Jesionek-Kupnicka, D., Pasz-Walczak, G., Watala, C., Kordek, R. (2006). Cyclin E Expression in Operable Breast Cancer Quantified Using Real-Time RT-PCR: A Comparative Study with Immunostaining. Jpn J Clin Oncol 36: 142-149 [Abstract] [Full Text]  
• Saez, R., Molina, M. A., Ramsey, E. E., Rojo, F., Keenan, E. J., Albanell, J., Lluch, A., Garcia-Conde, J., Baselga, J., Clinton, G. M. (2006). p95HER-2 Predicts Worse Outcome in Patients with HER-2-Positive Breast Cancer. Clin. Cancer Res. 12: 424-431 [Abstract] [Full Text]  
• Libertini, S. J., Robinson, B. S., Dhillon, N. K., Glick, D., George, M., Dandekar, S., Gregg, J. P., Sawai, E., Mudryj, M. (2005). Cyclin E Both Regulates and Is Regulated by Calpain 2, a Protease Associated with Metastatic Breast Cancer Phenotype. Cancer Res. 65: 10700-10708 [Abstract] [Full Text]  
• Hu, X., Washington, S., Verderame, M. F., Manni, A. (2005). Interaction between Polyamines and the Mitogen-Activated Protein Kinase Pathway in the Regulation of Cell Cycle Variables in Breast Cancer Cells. Cancer Res. 65: 11026-11033 [Abstract] [Full Text]  
• Colozza, M., Azambuja, E., Cardoso, F., Sotiriou, C., Larsimont, D., Piccart, M. J. (2005). Proliferative markers as prognostic and predictive tools in early breast cancer: where are we now?. Ann Oncol 16: 1723-1739 [Abstract] [Full Text]  
• Ungermannova, D., Gao, Y., Liu, X. (2005). Ubiquitination of p27Kip1 Requires Physical Interaction with Cyclin E and Probable Phosphate Recognition by SKP2. J. Biol. Chem. 280: 30301-30309 [Abstract] [Full Text]  
• Takahashi, T., Yamasaki, F., Sudo, T., Itamochi, H., Adachi, S., Tamamori-Adachi, M., Ueno, N. T. (2005). Cyclin A-associated kinase activity is needed for paclitaxel sensitivity. Molecular Cancer Therapeutics 4: 1039-1046 [Abstract] [Full Text]  
• Butt, A. J, McNeil, C. M, Musgrove, E. A, Sutherland, R. L (2005). Downstream targets of growth factor and oestrogen signalling and endocrine resistance: the potential roles of c-Myc, cyclin D1 and cyclin E. Endocr Relat Cancer 12: S47-S59 [Abstract] [Full Text]  
• Arnold, A., Papanikolaou, A. (2005). Cyclin D1 in Breast Cancer Pathogenesis. JCO 23: 4215-4224 [Abstract] [Full Text]  
• Safar, A. M., Spencer, H. III, Su, X., Coffey, M., Cooney, C. A., Ratnasinghe, L. D., Hutchins, L. F., Fan, C.-Y. (2005). Methylation Profiling of Archived Non-Small Cell Lung Cancer: A Promising Prognostic System. Clin. Cancer Res. 11: 4400-4405 [Abstract] [Full Text]  
• Yeretssian, G., Lecocq, M., Lebon, G., Hurst, H. C., Sakanyan, V. (2005). Competition on Nitrocellulose-immobilized Antibody Arrays: From Bacterial Protein Binding Assay to Protein Profiling in Breast Cancer Cells. Mol. Cell. Proteomics 4: 605-617 [Abstract] [Full Text]  
• Chappuis, P. O., Donato, E., Goffin, J. R., Wong, N., Begin, L. R., Kapusta, L. R., Brunet, J.-S., Porter, P., Foulkes, W. D. (2005). Cyclin E expression in breast cancer: predicting germline BRCA1 mutations, prognosis and response to treatment. Ann Oncol 16: 735-742 [Abstract] [Full Text]  
• Wingate, H., Zhang, N., McGarhen, M. J., Bedrosian, I., Harper, J. W., Keyomarsi, K. (2005). The Tumor-specific Hyperactive Forms of Cyclin E Are Resistant to Inhibition by p21 and p27. J. Biol. Chem. 280: 15148-15157 [Abstract] [Full Text]  
• Irie, A., Yamauchi, A., Kontani, K., Kihara, M., Liu, D., Shirato, Y., Seki, M., Nishi, N., Nakamura, T., Yokomise, H., Hirashima, M. (2005). Galectin-9 as a Prognostic Factor with Antimetastatic Potential in Breast Cancer. Clin. Cancer Res. 11: 2962-2968 [Abstract] [Full Text]  
• Garcia, H. H., Brar, G. A., Nguyen, D. H. H., Bjeldanes, L. F., Firestone, G. L. (2005). Indole-3-Carbinol (I3C) Inhibits Cyclin-dependent Kinase-2 Function in Human Breast Cancer Cells by Regulating the Size Distribution, Associated Cyclin E Forms, and Subcellular Localization of the CDK2 Protein Complex. J. Biol. Chem. 280: 8756-8764 [Abstract] [Full Text]  
• Lu, M., Kwan, T., Yu, C., Chen, F., Freedman, B., Schafer, J. M., Lee, E.-J., Jameson, J. L., Jordan, V. C., Cryns, V. L. (2005). Peroxisome Proliferator-activated Receptor {gamma} Agonists Promote TRAIL-induced Apoptosis by Reducing Survivin Levels via Cyclin D3 Repression and Cell Cycle Arrest. J. Biol. Chem. 280: 6742-6751 [Abstract] [Full Text]  
• Bales, E., Mills, L., Milam, N., McGahren-Murray, M., Bandyopadhyay, D., Chen, D., Reed, J. A., Timchenko, N., van den Oord, J. J., Bar-Eli, M., Keyomarsi, K., Medrano, E. E. (2005). The Low Molecular Weight Cyclin E Isoforms Augment Angiogenesis and Metastasis of Human Melanoma Cells In vivo. Cancer Res. 65: 692-697 [Abstract] [Full Text]  
• Brzezinski, J., Migodzinski, A., Toczek, A., Tazbir, J., Dedecjus, M. (2005). Patterns of Cyclin E, Retinoblastoma Protein, and p21Cip1/WAF1 Immunostaining in the Oncogenesis of Papillary Thyroid Carcinoma. Clin. Cancer Res. 11: 1037-1043 [Abstract] [Full Text]  
• Dejmek, J., Leandersson, K., Manjer, J., Bjartell, A., Emdin, S. O., Vogel, W. F., Landberg, G., Andersson, T. (2005). Expression and Signaling Activity of Wnt-5a/Discoidin Domain Receptor-1 and Syk Plays Distinct but Decisive Roles in Breast Cancer Patient Survival. Clin. Cancer Res. 11: 520-528 [Abstract] [Full Text]  
• Hayami, R., Sato, K., Wu, W., Nishikawa, T., Hiroi, J., Ohtani-Kaneko, R., Fukuda, M., Ohta, T. (2005). Down-regulation of BRCA1-BARD1 Ubiquitin Ligase by CDK2. Cancer Res. 65: 6-10 [Abstract] [Full Text]  
• Pruneri, G., Pignataro, L., Valentini, S., Fabris, S., Maisonneuve, P., Carboni, N., Pece, S., Capra, M., Del Curto, B., Neri, A., Viale, G. (2005). Cyclin D3 Immunoreactivity Is an Independent Predictor of Survival in Laryngeal Squamous Cell Carcinoma. Clin. Cancer Res. 11: 242-248 [Abstract] [Full Text]  
• Treilleux, I., Blay, J.-Y., Bendriss-Vermare, N., Ray-Coquard, I., Bachelot, T., Guastalla, J.-P., Bremond, A., Goddard, S., Pin, J.-J., Barthelemy-Dubois, C., Lebecque, S. (2004). Dendritic Cell Infiltration and Prognosis of Early Stage Breast Cancer. Clin. Cancer Res. 10: 7466-7474 [Abstract] [Full Text]  
• Cianfrocca, M., Goldstein, L. J. (2004). Prognostic and Predictive Factors in Early-Stage Breast Cancer. The Oncologist 9: 606-616 [Abstract] [Full Text]  
• Osborne, C., Wilson, P., Tripathy, D. (2004). Oncogenes and Tumor Suppressor Genes in Breast Cancer: Potential Diagnostic and Therapeutic Applications. The Oncologist 9: 361-377 [Abstract] [Full Text]  
• Louie, M. C., Zou, J. X., Rabinovich, A., Chen, H.-W. (2004). ACTR/AIB1 Functions as an E2F1 Coactivator To Promote Breast Cancer Cell Proliferation and Antiestrogen Resistance. Mol. Cell. Biol. 24: 5157-5171 [Abstract] [Full Text]  
• Nevalainen, M. T., Xie, J., Torhorst, J., Bubendorf, L., Haas, P., Kononen, J., Sauter, G., Rui, H. (2004). Signal Transducer and Activator of Transcription-5 Activation and Breast Cancer Prognosis. JCO 22: 2053-2060 [Abstract] [Full Text]  
• Staalesen, V., Leirvaag, B., Lillehaug, J. R., Lonning, P. E. (2004). Genetic and Epigenetic Changes in p21 and p21B Do Not Correlate with Resistance to Doxorubicin or Mitomycin and 5-Fluorouracil in Locally Advanced Breast Cancer. Clin. Cancer Res. 10: 3438-3443 [Abstract] [Full Text]  
• Akli, S., Zheng, P.-J., Multani, A. S., Wingate, H. F., Pathak, S., Zhang, N., Tucker, S. L., Chang, S., Keyomarsi, K. (2004). Tumor-Specific Low Molecular Weight Forms of Cyclin E Induce Genomic Instability and Resistance to p21, p27, and Antiestrogens in Breast Cancer. Cancer Res. 64: 3198-3208 [Abstract] [Full Text]  
• Shackney, S. E., Smith, C. A., Pollice, A., Brown, K., Day, R., Julian, T., Silverman, J. F. (2004). Intracellular Patterns of Her-2/neu, ras, and Ploidy Abnormalities in Primary Human Breast Cancers Predict Postoperative Clinical Disease-Free Survival. Clin. Cancer Res. 10: 3042-3052 [Abstract] [Full Text]  
• Pandya, A. Y., Talley, L. I., Frost, A. R., Fitzgerald, T. J., Trivedi, V., Chakravarthy, M., Chhieng, D. C., Grizzle, W. E., Engler, J. A., Krontiras, H., Bland, K. I., LoBuglio, A. F., Lobo-Ruppert, S. M., Ruppert, J. M. (2004). Nuclear Localization of KLF4 Is Associated with an Aggressive Phenotype in Early-Stage Breast Cancer. Clin. Cancer Res. 10: 2709-2719 [Abstract] [Full Text]  
• Harwell, R. M., Mull, B. B., Porter, D. C., Keyomarsi, K. (2004). Activation of Cyclin-dependent Kinase 2 by Full Length and Low Molecular Weight Forms of Cyclin E in Breast Cancer Cells. J. Biol. Chem. 279: 12695-12705 [Abstract] [Full Text]  
• Lindahl, T., Landberg, G., Ahlgren, J., Nordgren, H., Norberg, T., Klaar, S., Holmberg, L., Bergh, J. (2004). Overexpression of cyclin E protein is associated with specific mutation types in the p53 gene and poor survival in human breast cancer. Carcinogenesis 25: 375-380 [Abstract] [Full Text]  
• Keenan, S. M., Lents, N. H., Baldassare, J. J. (2004). Expression of Cyclin E Renders Cyclin D-CDK4 Dispensable for Inactivation of the Retinoblastoma Tumor Suppressor Protein, Activation of E2F, and G1-S Phase Progression. J. Biol. Chem. 279: 5387-5396 [Abstract] [Full Text]  
• Lucas, J. J., Domenico, J., Gelfand, E. W. (2004). Cyclin-Dependent Kinase 6 Inhibits Proliferation of Human Mammary Epithelial Cells. Mol Cancer Res 2: 105-114 [Abstract] [Full Text]  
• Leppa, S., Saarto, T., Vehmanen, L., Blomqvist, C., Elomaa, I. (2004). A High Serum Matrix Metalloproteinase-2 Level Is Associated with an Adverse Prognosis in Node-Positive Breast Carcinoma. Clin. Cancer Res. 10: 1057-1063 [Abstract] [Full Text]  
• Muller, H. M., Widschwendter, A., Fiegl, H., Ivarsson, L., Goebel, G., Perkmann, E., Marth, C., Widschwendter, M. (2003). DNA Methylation in Serum of Breast Cancer Patients: An Independent Prognostic Marker. Cancer Res. 63: 7641-7645 [Abstract] [Full Text]  
• Davol, P. A., Bagdasaryan, R., Elfenbein, G. J., Maizel, A. L., Frackelton, A. R. Jr. (2003). Shc Proteins Are Strong, Independent Prognostic Markers for Both Node-Negative and Node-Positive Primary Breast Cancer. Cancer Res. 63: 6772-6783 [Abstract] [Full Text]  
• Goldhirsch, A., Wood, W. C., Gelber, R. D., Coates, A. S., Thurlimann, B., Senn, H.-J. (2003). Meeting Highlights: Updated International Expert Consensus on the Primary Therapy of Early Breast Cancer. JCO 21: 3357-3365 [Abstract] [Full Text]  
• Roukos, D. H., Kappas, A. M., Agnantis, N. J. (2003). Perspectives and Risks of Breast-Conservation Therapy for Breast Cancer. Ann. Surg. Oncol. 10: 718-721 [Full Text]  
• Fan, Y., Borowsky, A. D., Weiss, R. H. (2003). An Antisense Oligodeoxynucleotide to p21Waf1/Cip1 Causes Apoptosis in Human Breast Cancer Cells. Molecular Cancer Therapeutics 2: 773-782 [Abstract] [Full Text]  
• Kang, Y., D'Hondt, L., Andre, M., Canon, J.-L., Yee, D., Rabinowitz, I., Bedrosian, I., Tucker, S. L., Keyomarsi, K. (2003). Cyclin E in Breast Cancer. NEJM 348: 1063-1064 [Full Text]  
• (2002). Minerva. BMJ 325: 1310-1310 [Full Text]